Erratum: Golimumab, a new human anti–tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

li id=au1Joel Kremer li id=au2Christopher Ritchlin li id=au3Alan Mendelsohn li id=au4Daniel Baker li id=au5Lilianne Kim li id=au6Zhenhua Xu li id=au7John Han li id=au8Peter Taylor

首页> 外文期刊>Arthritis & Rheumatism >Erratum: Golimumab, a new human anti–tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

【24h】

Erratum: Golimumab, a new human anti–tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

机译：勘误：Golimumab，一种新型的人类抗肿瘤坏死因子抗体，在活动性类风湿关节炎患者中静脉给药：III期随机，双盲，安慰剂对照研究的48周疗效和安全性结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

No abstract is available for this article.

机译：本文没有摘要。

著录项

来源
《Arthritis & Rheumatism》 |2010年第10期|p.3130|共1页
作者
li id=au1Joel Kremer li id=au2Christopher Ritchlin li id=au3Alan Mendelsohn li id=au4Daniel Baker li id=au5Lilianne Kim li id=au6Zhenhua Xu li id=au7John Han li id=au8Peter Taylor;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Golimumab, a new human anti–tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study † [J] . Joel Kremer, Christopher Ritchlin, Alan Mendelsohn, Arthritis & Rheumatism . 2010,第4期

机译：Golimumab，一种新型的人类抗肿瘤坏死因子抗体，在活动性类风湿关节炎患者中静脉给药：III期随机，双盲，安慰剂对照研究的48周疗效和安全性结果†
2. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. [J] . Kremer J, Ritchlin C, Mendelsohn A, Arthritis and Rheumatism . 2010,第4期

机译：戈利木单抗，一种新型的人类抗肿瘤坏死因子α抗体，在活动性类风湿性关节炎患者中静脉给药：III期随机，双盲，安慰剂对照研究的48周疗效和安全性结果。
3. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. [J] . Kremer J, Ritchlin C, Mendelsohn A, Arthritis and Rheumatism . 2010,第4期

机译：戈利木单抗，一种新型的人类抗肿瘤坏死因子α抗体，在活动性类风湿性关节炎患者中静脉给药：III期随机，双盲，安慰剂对照研究的48周疗效和安全性结果。
4. Predictors of Infection in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents [D] . Liu, Tasia 2017

机译：类风湿关节炎患者使用抗肿瘤坏死因子药物的感染预测因子
5. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter randomized double-blind placebo-controlled phase 3 GO-AFTER study [O] . Josef S Smolen, Jonathan Kay, Mittie Doyle, 2015

机译：用肿瘤坏死因子α抑制剂治疗后活动性类风湿关节炎患者的戈利木单抗：多中心随机双盲安慰剂对照3期GO-AFTER研究中长达五年的治疗结果
6. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. [O] . Kremer, J, Ritchlin, C, Mendelsohn, A, 2010

机译：戈利木单抗，一种新型的人类抗肿瘤坏死因子α抗体，在活动性类风湿性关节炎患者中静脉内给药：一项III期随机，双盲，安慰剂对照研究的48周疗效和安全性结果。

Erratum: Golimumab, a new human anti–tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

摘要

著录项

相似文献

相关主题

期刊订阅